Organon
https://www.organon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Organon
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
Organon Welcomes Prospect Of Interchangeability ‘Boost’ – But Pricing Still Key
Organon’s CEO Kevin Ali talked at length about the company’s launch of its Hadlima biosimilar version of Humira in the US during the company’s Q2 earnings call, following recent news it was looking to file for an interchangeability designation.
Stelara Biosimilars In Wings, Will Proposed Red Tape Elimination Act Aid Biosimilars Push?
As Stelara biosimilars wait in the wings, proposed legislation in the US could ease the path to commercialization. The Draft Red Tape Elimination Act aims to remove a requirement for switching studies. Opposition to the bill is expected, but if passed how much will the Act move the biosimilars needle in the country?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alydia Health
- Forendo Pharma Oy
- Organon NV
- Organon & Co.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice